Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
72 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Show Display Options
Rank Status Study
21 Not yet recruiting Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Conditions: Breast Cancer Female NOS;   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer;   Tubular Breast Cancer Stage III
Interventions: Drug: Denosumab;   Drug: nab-Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab
22 Recruiting Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
Condition: Invasive Breast Cancer
Interventions: Drug: Vandetanib;   Other: Placebo
23 Not yet recruiting The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC)
Condition: Breast Cancer
Interventions: Drug: Lidocaine;   Drug: Sevoflurane;   Drug: TIVA-TCI;   Drug: Acetaminophen;   Drug: Tramadol;   Drug: Neostigmine;   Drug: Atropine;   Device: BIS
24 Recruiting Persistent Organic Pollutants and Breast Cancers (POPCASE)
Condition: Breast Cancer
Interventions: Procedure: Breast cancer surgery;   Procedure: plastic surgery
25 Recruiting Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Pembrolizumab;   Drug: Nab-Paclitaxel
26 Recruiting Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: Abemaciclib
27 Recruiting PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Condition: Breast Cancer
Interventions: Drug: Neoadjuvant tamoxifen + goserelin (premenopausal women);   Drug: Neoadjuvant letrozole (postmenopausal women);   Drug: Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone);   Drug: Neoadjuvant docetaxel + cyclophosphamide;   Drug: Neoadjuvant docetaxel;   Drug: Neoadjuvant docetaxel + trastuzumab + pertuzumab;   Drug: Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab;   Drug: Neoadjuvant olaparib;   Drug: Neoadjuvant olaparib + carboplatin (if lack of response to olaparib alone);   Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection;   Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes;   Drug: Adjuvant trastuzumab;   Drug: Adjuvant letrozole (postmenopausal women);   Drug: Adjuvant tamoxifen + goserelin (premenopausal women);   Drug: Adjuvant palbociclib (if palbociclib given neoadjuvant);   Drug: Adjuvant Epirubicin+ Cyclophosphamide
28 Recruiting Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: MK-3475
29 Recruiting Adjuvant AI Combined With Zoladex
Condition: Breast Cancer
Interventions: Drug: Zoladex+AI;   Drug: TAM
30 Recruiting HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
Condition: HER-2 Positive Breast Cancer
Interventions: Drug: T-DM1;   Procedure: 89Zr-trastuzumab
31 Not yet recruiting Targeting the Hippo Transducer TAZ in Breast Cancer With Statins
Condition: Breast Neoplasms
Intervention: Drug: Atorvastatin
32 Recruiting The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients
Condition: Haematological Abnormality
Interventions: Dietary Supplement: Jobelyn + Cyclophosphamide-Epirubicin6;   Drug: Placebo + Cyclophosphamide - Epirubicin 6
33 Recruiting Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Durvalumab
34 Recruiting Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
Condition: Triple Negative Breast Cancer
Intervention: Drug: Afatinib
35 Recruiting Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Drug: Everolimus;   Drug: TRC105
36 Recruiting Study of Preoperative Boost Radiotherapy
Condition: Breast Cancer
Intervention: Radiation: Single fraction of 10Gy
37 Recruiting Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Lenvatinib + Letrozole
38 Not yet recruiting SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
Conditions: Metastatic Non-small Cell Lung Cancer;   Metastatic Triple-negative Breast Cancer
Interventions: Biological: ADV/HSV-tk;   Drug: Valacyclovir;   Radiation: SBRT;   Drug: Pembrolizumab
39 Recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Low dose FRα vaccine;   Drug: Cyclophosphamide;   Biological: High dose FRα vaccine
40 Recruiting Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib;   Biological: Trastuzumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.